FGFR2 as A Prognostic and Predictive Marker in Colorectal Adenocarcinoma Based on TILs Grade
Abstract
BACKGROUND: Colorectal cancer remains a serious health problem due to its high incidence and mortality rate each year. Histopathological grades and tumor-infiltrating lymphocytes (TILs) are associated with patient’s outcome. Fibroblast growth factor receptor 2 (FGFR2) overexpression is correlated with a worse prognosis in colorectal adenocarcinoma patients. Unfortunately, there are not many studies investigating the relationship between FGFR2 with histopathological grade and TILs in Indonesia. This study was conducted to analyze the correlation between FGFR2 expression with histopathological grade and TILs grade in colorectal adenocarcinoma.
METHODS: Immunohistochemistry examination using FGFR2 rabbit polyclonal antibody was performed on 94 paraffin-embedded colorectal adenocarcinoma blocks and its expression was examined using a light microscope. The relationship between FGFR2 expression with histopathological grade and TILs grade in colorectal adenocarcinoma was statistically analyzed.
RESULTS: Of the 94 samples examined, low grade adenocarcinoma was more common (n=76), of which 60.5% showed high FGFR2 expression. While in high grade adenocarcinoma, 83.3% of the samples showed high FGFR2 expression. In low grade TILs (n=30), 80% showed strong FGFR2 expression. While in high grade TILs (n=17), 64.7% showed weak FGFR2 expression. Based on statistical analysis, there was a significant correlation between FGFR2 expression and TILs grade (p=0.008). However, there was no significant association with histopathological grade (p=0.127).
CONCLUSION: The significant correlation between FGFR2 expression and TILs grade suggests that FGFR2 may be used as a prognostic and predictive marker in colorectal adenocarcinoma.
KEYWORDS: FGFR2, Colorectal adenocarcinoma, TILs, Histopathological grade
Full Text:
PDFReferences
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-63, CrossRef.
Harjanti DA, Murtono C, Suryawinata K, Halim A, Wiryokusuma MF, Djitro TB. John Cunningham virus T-antigen expression on mild and severe dysplasia adenomatous polyp, low and high grade adenocarcinoma of the colon. Mol Cell Biomed Sci. 2019; 3(1): 7-12, CrossRef.
Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: Epidemiology, risk factors, and prevention. Cancers. 2024; 16(8): 1530, CrossRef.
Miskad UA, Akil F, Cangara MH, Dahlan H, Hutasoit GA, Ilyasa MR. Snail expression is positively correlated with depth of invasion in colorectal carcinoma. Indones Biomed J. 2024; 16(6): 553-9, CrossRef.
Tedjasaputra TR, Hatta M, Massi MN, Natzir R, Patellongi I, Simadibrata M, et al. Risk assessment in hereditary colorectal cancer family by using APC and MSH2 mRNA gene expression and Bayesian analysis. Indones Biomed J. 2020; 12(4): 368-75, CrossRef.
Nagtegaal ID, Arends MJ, Salto Tellez M. Tumours of the colon and rectum. In: WHO Classification of Tumours Digestive System Tumours. 5th ed. Geneva: World Health Organization; 2019, article.
Odze RDr, Goldblum JR. Epithelial neoplasms of the large intestine. In: Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 3rd ed. Philadelphia: Elsevier Saunders; 2014, article.
Rhee YY, Kim KJ, Kang GH. CpG island methylator phenotype-high colorectal cancers and their prognostic implications and relationships with the serrated neoplasia pathway. Gut Liver. 2017; 11(1): 38-46, CrossRef.
Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine. 2018; 97(9): e0019, CrossRef.
Theodora I, Sudiana IK, Budipramana VS, Erwin F, Dewi S, Novita BD. Tumor differentiation is correlated with estrogen receptor beta (ERβ) expression but not with interleukin-6 (IL-6) expression in colorectal carcinoma. Indones Biomed J. 2024; 16(5): 481-6, CrossRef.
Wulandari F, Hanifa M. Integrative bioinformatics reveals the lactate dehydrogenase B (LDHB) significance in colon adenocarcinoma. Mol Cell Biomed Sci. 2023; 7(2): 98-108, CrossRef.
Langrand-Escure J, Diao P, Garcia MA, Wang G, Guy JB, Espenel S, et al. Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional survey. Sci Rep. 2018; 8(1): 10708, CrossRef.
Li CJ, Zhang X, Fan GW. Updates in colorectal cancer stem cell research. J Can Res Ther. 2014; 10(8): 233-9, CrossRef.
Tiong KH, Mah LY, Leong CO. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis. 2013; 18(12): 1447-68, CrossRef.
Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast growth factor receptors (FGFRs): Structures and small molecule inhibitors. Cells. 2019; 8(6): 614, CrossRef.
Zhou WY, Zheng H, Du XL, Yang JL, Zhou WY, Zheng H, et al. Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med. 2016; 13(2): 260-8, CrossRef.
Ratti M, Orlandi E, Hahne JC, Vecchia S, Citterio C, Anselmi E, et al. Targeting FGFR pathways in gastrointestinal cancers: New Frontiers of Treatment. Biomedicines. 2023; 11(10): 2650, CrossRef.
Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017; 8(9): 16052-74, CrossRef.
Pacini L, Jenks AD, Lima NC, Huang PH. Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer. Cells. 2021; 10(5): 1154, CrossRef.
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017; 113: 256-67, CrossRef.
Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-infiltrating lymphocytes in colorectal cancer: The fundamental indication and application on immunotherapy. Front Immunol. 2022; 12: 808964, CrossRef.
Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully. Biomed Pharmacother. 2020: 132: 110873, CrossRef.
Clearesta KE, Mambu T, Tjandra F, Langi FG. Hubungan antara tumor-infiltrating lymphocytes dengan stadium dan derajat diferensiasi adenokarsinoma kolorektal. Medical Scope Journal. 2023; 6(1): 99-105, CrossRef.
Miskad UA, Hamzah N, Cangara MH, Nelwan BJ, Masadah R, Wahid S. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma. Minerva Med. 2020; 111(4): 337-43, CrossRef.
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 2017; 8: 561, CrossRef.
Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, et al. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS ONE. 2018; 13(4): e0192744, CrossRef.
Hu M, Zhang S. Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma. Transl Cancer Res TCR. 2022; 11(9): 3222-34, CrossRef.
Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: A systematic review and meta-analysis. Sci Rep. 2020; 10(1): 3360, CrossRef.
Paijens ST, Vledder A, De Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021; 18(4): 842-59, CrossRef.
Ruan R, Li L, Li X, Huang C, Zhang Z, Zhong H, et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Mol Cancer. 2023; 22(1): 60, CrossRef.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26(1): 677-704, CrossRef.
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8): 486-99, CrossRef.
Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends in Immunology. 2015; 36(4): 265-76, CrossRef.
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024; 23(1): 108, CrossRef.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3): 727-42, PMID.
DOI: https://doi.org/10.18585/inabj.v17i2.3523
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
